Modulators of cystic fibrosis transmembrane conductance regulator
US-2019055220-A1 · Feb 21, 2019 · US
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
US12415798B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12415798-B2 |
| Application number | US-202217899672-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 31, 2022 |
| Priority date | Dec 8, 2017 |
| Publication date | Sep 16, 2025 |
| Grant date | Sep 16, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure provides processes for preparing a compound of Formula (I):
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula viii: Compound 6 a salt or deuterated derivative thereof, wherein R 1 is a protecting group; and R b is C 1 -C 4 alkyl. 2. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc), benzyl (Bn), tetrahydropyranyl (THP), 9-fluorenylmethyl carbamate (Fmoc), benzyl carbamate (Cbz), acetamide, trifluoroacetamide, triphenylmethylamine, benzylideneamine, and p-toluenesulfonamide. 3. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc), benzyl (Bn), and tetrahydropyranyl (THP). 4. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc). 5. The compound, salt, or deuterated derivative according to claim 1 , wherein R b is ethyl.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
One oxygen atom attached in position 3 or 5 · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12415798B2 cover?
- The disclosure provides processes for preparing a compound of Formula (I):
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).